In melanoma cells harboring the NRAS mutation, the mutated NRAS protein needs CRAF to activate the MEK/ERK pathway [34], and the BRAF protein is phosphorylated by ERK on S151 near the RAS binding domain, which results in the inhibition of the NRAS/BRAF interaction [35]. The gene discussed is MAP2K7; the disease is melanoma.